24310-36-9

Basic information

• Product Name: 1-(TOLUENE-4-SULFONYL)-1,2,3,4-TETRAHYDROBENZO[B]AZEPIN-5-ONE
• Synonyms: 1-(TOLUENE-4-SULFONYL)-1,2,3,4-TETRAHYDROBENZO[B]AZEPIN-5-ONE;1,2,3,4-Tetrahydro-1-[(4-methylphenyl)sulfonyl]-5H-1-benzazepin-5-one;1-Tosyl-2,3,4,5-tetrahydro-1H-1-benzazepine-5-one;1-Tosyl-2,3-dihydro-1H-1-benzazepine-5(4H)-one;1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one;1-[(4-Methylbenzene)sulfonyl]-2,3,4,5-tetrahydro-1H-1-benzazepin-5-one;1,2,3,4-tetrahydro-1-tosylbenzo[b]azepin-5-one;1,2,3,4-tetrahydro-1-(4-Methylbenzenesulfonyl)-1-benzazepin-5-one
• CAS NO: 24310-36-9
• Molecular Formula: C₁₇H₁₇NO₃S
• Molecular Weight: 315.39
• EINECS: 1312995-182-4
• Product Categories: pharmacetical
• Mol File: 24310-36-9.mol
• Article Data: 14

Chemical Properties

• Melting Point: 126 °C(Solv: methanol (67-56-1))
• Boiling Point: 489.668 ºC at 760 mmHg
• Flash Point: 249.9 ºC
• Appearance: /
• Density: 1.287 g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.614
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -3?+-.0.20(Predicted)
• CAS DataBase Reference: 1-(TOLUENE-4-SULFONYL)-1,2,3,4-TETRAHYDROBENZO[B]AZEPIN-5-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(TOLUENE-4-SULFONYL)-1,2,3,4-TETRAHYDROBENZO[B]AZEPIN-5-ONE(24310-36-9)
• EPA Substance Registry System: 1-(TOLUENE-4-SULFONYL)-1,2,3,4-TETRAHYDROBENZO[B]AZEPIN-5-ONE(24310-36-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 24310-36-9(Hazardous Substances Data)

Usage

Uses

1,2,3,4-Tetrahydro-1-[(4-methylphenyl)sulfonyl]-5H-1-benzazepin-5-one is an intermediate used to prepare nonpeptide vasopressin V2 receptor antagonist tetrahydro-1H-benzazepines. It is also used to synthesize 4''-[(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-yl)carbonyl]-2-phenylbenzanilide derivatives as non-peptide arginine vasopressin antagonists for both V1A and V2 receptors.

InChI:InChI=1/C17H17NO3S/c1-13-8-10-14(11-9-13)22(20,21)18-12-4-7-17(19)15-5-2-3-6-16(15)18/h2-3,5-6,8-11H,4,7,12H2,1H3

Upstream product

• 100627-39-2 N-(3-ethoxycarbonyl-propyl)-N-(toluene-4-sulfonyl)-anthranilic acid methyl ester 
• 2969-81-5 Ethyl 4-bromobutyrate 
• 50998-74-8 methyl N-tosylanthranilate 
• 103151-64-0 4-[N-(toluene-4-sulfonyl)-anilino]-butyric acid 
• 20426-63-5 1-(p-Tolylsulfonyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 877858-22-5 ethyl 2,3-dihydro-5-hydroxy-1-tosyl-1H-1-benzazepine-4-carboxylate 
• 851044-96-7 5-oxo-1-tosyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine-4-carboxylic acid methyl ester 
• 54620-98-3 ethyl 5-oxo-1-tosyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine-4-carboxylate 
• 98-59-9 p-toluenesulfonyl chloride 
• 105895-93-0 methyl 2-{(3-cyanopropyl)[(4-methylphenyl)sulfonyl]amino}benzoate 
• 134-20-3 2-carbomethoxyaniline 
• 125715-24-4 1-(2-nitrophenyl)but-3-en-1-ol 
• 881417-10-3 N-{2-[1-tert-butyldimethylsilyloxy-4-(tetrahydropyran-2-yloxy)butyl]phenyl}-p-toluenesulfonamide 
• 881417-11-4 N-{2-[1-hydroxy-4-(tetrahydropyran-2-yloxy)butyl]phenyl}-p-toluenesulfonamide 

Downstream Products

• 168163-93-7 4-fluoro-1-(p-toluenesulfonyl)-1,2,3,4-tetrahydro-5H-1-benzoazepin-5-one 
• 130719-76-5 ethyl {1-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetate 
• 876048-15-6 2-[1-(4-methylphenylsulphonyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yliden] malononitrile 
• 155061-62-4 5-dimethylamino-2,3,4,5-tetrahydro-1H-benzoazepine 
• 181210-18-4 Dimethyl-[1-(toluene-4-sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl]-amine 
• 200122-35-6 6-(4-nitrobenzoyl)-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxylic acid 

Relevant articles and documents

Photoactive NO hybrids with pseudo-zero-order release kinetics for antimicrobial applications

Bacterial infection is a major threat to the health and life of humans due to the development of drug resistance, which is related to biofilm formation. Nitric oxide (NO) has emerged as an important factor in regulating biofilm formation. In order to harness the potential benefits of NO and develop effective antibacterial agents, we designed and synthesized a new class of NO hybrids in which the active scaffold benzothienoazepine was tagged with a nitroso group and further conjugated with quaternary ammoniums or phosphoniums. The temporal release of NO from these hybrids can be achieved by photoactivation. Interestingly, the NO release follows a pseudo-zero-order kinetics, which is easily determined by measuring the fluorescent benzothienoazepine or NO. Compared to the positive control ciprofloxacin, the NO hybrid with triphenyl phosphonium (TPP) exhibited more effective activity against S. aureus biofilm in darkness. Irradiation of the NO hybrid led to higher inhibition against S. aureus biofilm compared to the parental NO hybrid in darkness or the corresponding NO-released product, indicating the combined effect of NO and the NO-released product. Therefore, this new class of NO hybrids includes very promising antimicrobial agents and this work provides a new way for the design of highly effective antimicrobial agents. This journal is

LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism

Oxytocin (OT) and its receptor (OT-R) are implicated in the etiology of autism spectrum disorders (ASD), and OT-R is a potential target for therapeutic intervention. Very few nonpeptide oxytocin agonists have currently been reported. Their molecular and in vivo pharmacology remain to be clarified, and none of them has been shown to be efficient in improving social interaction in animal models relevant to ASD. In an attempt to rationalize the design of centrally active nonpeptide full agonists, we studied in a systematic way the structural determinants of the affinity and efficacy of representative ligands of the V1a and V2 vasopressin receptor subtypes (V1a-R and V2-R) and of the oxytocin receptor. Our results confirm the subtlety of the structure-affinity and structure-efficacy relationships around vasopressin/oxytocin receptor ligands and lead however to the first nonpeptide OT receptor agonist active in a mouse model of ASD after peripheral ip administration.